

Effective Date: 9/1/2024
Reviewed: 6/2024, 4/2025, 6/2026
Scope: Medicaid

Drugs to Reduce Serum Phosphorus in Chronic Kidney Disease on Dialysis:

Ferric citrate (generic Auryxia)

Velphoro (sucroferric oxyhydroxide)

Xphozah (tenapanor hydrochloride)

POLICY

I. CRITERIA FOR APPROVAL

An authorization of 12 months may be granted when all the following criteria are met:

- A. The requested drug is being prescribed to reduce serum phosphorus in an adult patients 18 years of age or older with chronic kidney disease (CKD) who is currently receiving dialysis for End Stage Renal Disease; OR if requesting Velphoro the patient is 9 years and older with CKD who is currently receiving dialysis for End Stage Renal Disease and being used to reduce serum phosphorus levels AND
- B. Documentation that the patient has experienced an intolerance or inadequate treatment response (with documentation of progressively or persistently elevated serum phosphate >5.5mg/dL) to at least two formulary phosphate binders: calcium acetate tablets OR capsules, sevelamer tablets OR packets, and/or lanthanum chew tablets; AND
- C. If the requested drug being prescribed for an adult for Velphoro (sucroferric oxyhydroxide) or Xphozah (tenapanor hydrochloride), the patient has experienced an intolerance or inadequate treatment response with documentation required of progressively or persistently elevated serum phosphate >5.5mg/dL when being treated with ferric citrate

II. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for all members who have documentation of a positive clinical response (e.g. reduction in serum phosphorus from pretreatment level)

III. QUANTITY LIMIT

- Ferric citrate 210 mg: 360 tablets per 30 days (12 tablets per day)
- Velphoro (sucroferric oxyhydroxide) 500 mg: 180 chew tablets per 30 days (6 tablets per day)
- Xphozah (tenapanor hydrochloride) 10 mg, 20 mg, 30 mg: 60 tablets per 30 days (2 tablets per day)

REFERENCES

1. Xphozah [package insert]. Waltham, MA: Ardelyx, Inc.; December 2024. Accessed May 2026.
2. Velphoro [package insert]. Waltham, MA: Fresenius Medical Care North America; April 2026. Accessed May 2026.
3. Auryxia [Prescribing Information]. New York, NY: Keryx Biopharmaceuticals, Inc.; June 2025. Accessed May 2026.
4. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed November 2, 2023.
5. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 11/2/2023).
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl.* 2017;7:1–59.